Skip to main content
Premium Trial:

Request an Annual Quote

Discovery Studio Gene 1.0, MetaProcessor 3.0, GenBank Release 130.0, Trembl 21.0


Accelrys, the San Diego-based subsidiary of Pharmacopeia, has released Discovery Studio Gene 1.0 (DS Gene), the first bioinformatics tool for the company’s Discovery Studio enterprise platform. According to Accelrys, DS Gene offers a user-friendly Windows-based interface to perform DNA and protein sequence analysis. It gives users access to Accelrys’ GCG Wisconsin Package and performs database searching, multiple sequence analysis, mapping, primer analysis, and motif searching.

DS Gene can be used as a stand-alone sequence analysis system or integrated into the company’s Discovery Studio platform using an Oracle-based groupware infrastructure called Discovery Studio Project Knowledge Manager.

In addition to DS Gene, Accelrys has also released DS ViewerPro, a molecular modeling and visualization tool, and DS MedChem Explorer, a pharmacophore modeling and design application, as part of the Discovery Studio suite.


United Devices of Austin, Texas, has released MetaProcessor 3.0, an update of its enterprise grid platform. The new version of the system incorporates web services standards such as XML, SOAP, and WSDL and complies with the Open Grid Services Architecture specification endorsed by the Global Grid Forum.


GenBank Release 130.0 is now available from the National Center for Biotechnology Information at and mirror sites ( and

Release 130.0 contains 20,648,748,345 base pairs and 17,471,130 entries, up by 1.576 billion base pairs and 701,147 sequence records from the April 129.0 release. Uncompressed, the 130.0 flat files require around 70.15 GB for the sequence files only. The ASN.1 version requires around 61.72 GB.


Trembl 21.0 is now available from the European Bioinformatics Institute at trembl. The supplement to Swiss-Prot was created from release 70 of the EMBL Nucleotide Sequence Database and contains 751,148 entries and 218,504,701 amino acids.


Filed under

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.